These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3719104)

  • 1. Metabolism of ara-C by blast cells from patients with ANLL.
    Ross DD; Thompson BW; Joneckis CC; Akman SA; Schiffer CA
    Blood; 1986 Jul; 68(1):76-82. PubMed ID: 3719104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
    Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
    Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
    Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
    Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
    Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calculation of individual dosage regimen of cytosine arabinoside (ara-C) based on metabolite levels in leukemic cells.
    Riva-Lavieille C; Ressayre C; Barra Y; Carcassonne Y; Iliadis A
    Ther Drug Monit; 1994 Aug; 16(4):375-9. PubMed ID: 7974627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
    Ehninger G; Proksch B; Wanner T; Schuler U; Busch FW; Schmidt H; Schleyer E; Jaschonek K; Hiddemann W
    Leukemia; 1992 Jun; 6(6):582-7. PubMed ID: 1602795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM; Rustum YM
    Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
    Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
    Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment.
    Rustum YM; Slocum HK; Wang G; Bakshi D; Kelly E; Buscaglia D; Wrzosek C; Early AP; Preisler H
    Med Pediatr Oncol; 1982; 10 Suppl 1():33-43. PubMed ID: 7162465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation.
    Freund A; Rössig C; Lanvers C; Gescher A; Hohenlöchter B; Jürgens H; Boos J
    Ann Oncol; 1999 Mar; 10(3):335-8. PubMed ID: 10355579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
    Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W
    Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W; Nowak B; Keating MJ
    Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview.
    Rustum YM; Raymakers RA
    Pharmacol Ther; 1992 Dec; 56(3):307-21. PubMed ID: 1301593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
    Tanaka M
    Leuk Res; 1993 Jul; 17(7):585-92. PubMed ID: 8326741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology.
    Wang LM; White JC; Capizzi RL
    Cancer Chemother Pharmacol; 1990; 25(6):418-24. PubMed ID: 2311169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    Leuk Lymphoma; 1993; 10 Suppl():109-14. PubMed ID: 8481660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.